Tekmira Pharma Initiates Clinical Trial With TKM-PLK1 - Quick Facts

(RTTNews) - Tekmira Pharmaceuticals Corp. (TKMR, TKM.TO) announced it has initiated a Phase I/II clinical trial with TKM-PLK1, its RNAi oncology therapeutic for the treatment of solid tumors. The trial will be a multi-center, single arm, open label study designed to measure efficacy using RECIST and tumor biomarkers for Gastrointestinal Neuroendocrine Tumor patients, as well as to evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1.

Tekmira will initiate another Phase I/II clinical trial with TKM-PLK1, enrolling patients with Hepatocellular Carcinoma, in the first half of 2014.